KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Net Margin (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Net Margin for 15 consecutive years, with 6.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 2084.0% year-over-year to 6.71%, compared with a TTM value of 8.45% through Dec 2025, up 2082.0%, and an annual FY2025 reading of 8.45%, up 2082.0% over the prior year.
  • Net Margin was 6.71% for Q4 2025 at Alnylam Pharmaceuticals, down from 23.43% in the prior quarter.
  • Across five years, Net Margin topped out at 23.43% in Q3 2025 and bottomed at 153.58% in Q3 2022.
  • Average Net Margin over 5 years is 55.22%, with a median of 57.68% recorded in 2023.
  • The sharpest move saw Net Margin soared 17327bps in 2023, then tumbled -4750bps in 2025.
  • Year by year, Net Margin stood at 99.97% in 2021, then surged by 38bps to 61.93% in 2022, then surged by 49bps to 31.35% in 2023, then surged by 55bps to 14.12% in 2024, then surged by 148bps to 6.71% in 2025.
  • Business Quant data shows Net Margin for ALNY at 6.71% in Q4 2025, 23.43% in Q3 2025, and 9.34% in Q2 2025.